Huang Yihung, Tilea Anca, Gillespie Brenda, Shahinian Vahakn, Banerjee Tanushree, Grubbs Vanessa, Powe Neil, Rios-Burrows Nilka, Pavkov Meda, Saran Rajiv
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Division of Nephrology, Department of Medicine, University of California, San Francisco, California; and.
J Am Soc Nephrol. 2017 Aug;28(8):2498-2510. doi: 10.1681/ASN.2016050543. Epub 2017 Mar 7.
Lower eGFR 1 year after kidney transplant is associated with shorter allograft and patient survival. We examined how practice changes in the past decade correlated with time trends in average eGFR at 1 year after kidney transplant in the United States in a cohort of 189,944 patients who received a kidney transplant between 2001 and 2013. We calculated the average eGFR at 1 year after transplant for the recipient cohort of each year using the appropriate Modification of Diet in Renal Disease equation depending on the prevailing methodology of creatinine measurement, and used linear regression to model the effects of practice changes on the national post-transplant eGFR trend. Between the 2001-2005 period and the 2011-2013 period, average 1-year post-transplant eGFR remained essentially unchanged, with differences of 1.34 (95% confidence interval, 1.03 to 1.65) ml/min per 1.73 m and 0.66 (95% confidence interval, 0.32 to 1.01) ml/min per 1.73 m among deceased and living donor kidney transplant recipients, respectively. Over time, the mean age of recipients increased and more marginal organs were used; adjusting for these trends unmasked a larger temporal improvement in post-transplant eGFR. However, changes in immunosuppression practice had a positive effect on average post-transplant eGFR and balanced out the negative effect of recipient/donor characteristics. In conclusion, average 1-year post-transplant eGFR remained stable, despite increasingly unfavorable attributes in recipients and donors. With an aging ESRD population and continued organ shortage, preservation of average post-transplant eGFR will require sustained improvement in immunosuppression and other aspects of post-transplant care.
肾移植后1年估算肾小球滤过率(eGFR)较低与移植肾及患者生存期较短相关。我们在美国189944例于2001年至2013年间接受肾移植的患者队列中,研究了过去十年间的医疗实践变化与肾移植后1年平均eGFR的时间趋势之间的相关性。我们根据肌酐测量的现行方法,使用适当的肾脏病饮食改良方程计算每年受者队列移植后1年的平均eGFR,并使用线性回归来模拟医疗实践变化对全国移植后eGFR趋势的影响。在2001 - 2005年期间和2011 - 2013年期间,移植后1年的平均eGFR基本保持不变,在 deceased 和活体供肾移植受者中,每1.73平方米分别相差1.34(95%置信区间,1.03至1.65)ml/分钟和0.66(95%置信区间,0.32至1.01)ml/分钟。随着时间的推移,受者的平均年龄增加,更多边缘器官被使用;对这些趋势进行调整后发现移植后eGFR有更大的时间性改善。然而,免疫抑制实践的变化对移植后平均eGFR有积极影响,并抵消了受者/供者特征的负面影响。总之,尽管受者和供者的属性越来越不利,但移植后1年的平均eGFR仍保持稳定。随着终末期肾病患者群体老龄化和器官持续短缺,保持移植后平均eGFR将需要免疫抑制及移植后护理其他方面的持续改善。